'''Stanford V''' (usually spoken as ''Stanford Five''), is a chemotherapy regimen (with accompanying radiation therapy) intended as a first-line treatment for Hodgkin lymphoma. The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens such as ABVD.<ref name="Bartlett_et_al_JCO1995">{{cite journal |vauthors=Bartlett NL, Rosenberg SA, Hoppe RT, etal |title=Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report |journal=J. Clin. Oncol. |volume=13 |issue=5 |pages=1080–1088 |year=1995 |doi=10.1200/JCO.1995.13.5.1080 |pmid=7537796 }}</ref> The chemical agents used are: * A mustard derivative such as cyclophosphamide, chlormethine or ifosfamide * Doxorubicin, an anti-tumor antibiotic * Vinblastine, an alkaloid cell toxin * Vincristine, another alkaloid cell toxin * Bleomycin, another anti-tumor antibiotic * Etoposide, a DNA toxin * Prednisone, a corticosteroid

==Drug Regimen== The chemotherapy part of Stanford V treatment can last anywhere from 8 to 12 weeks, depending on the staging of the disease. In many cases, this is followed by radiation therapy for anywhere from 2 to 6 weeks to the affected areas of the body.

Stanford V is a more rigorously administered form of chemotherapy, with treatments roughly twice as fast as those of other Hodgkin lymphoma treatments. However, in a randomized controlled study, Stanford V was inferior to ABVD.<ref name="pmid16172458">{{cite journal |title=ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi |journal=J. Clin. Oncol. |volume=23 |issue=36 |pages=9198–207 |year=2005 |pmid=16172458 |doi=10.1200/JCO.2005.02.907 |first1= PG |last1=Gobbi |first2=A |last2=Levis |first3=T |last3=Chisesi |first4=C |last4= Broglia | display-authors = 3 |doi-access=free |hdl=11380/3063 |hdl-access=free }}</ref> This study has been criticize for not adhering to the proper Stanford V protocol. Specifically, the radiation therapy component following chemotherapy was not properly administered in the Italian study. A retrospective study from the Memorial Sloan-Kettering Cancer Center displayed results similar to the Stanford Cancer Center's own experience. The study concluded that, "Stanford V with appropriate radiotherapy is a highly effective regimen for locally extensive and advanced HL."<ref name="pmid19759185">{{cite journal |vauthors=Edwards-Bennett SM, Jacks LM, Moskowitz CH, Wu EJ, Zhang Z, Noy A, Portlock CS, Straus DJ, Zelenetz AD, Yahalom J |title=Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience. |journal=Ann. Oncol. |volume=21 |issue=3 |pages=574–81 |year=2010 |pmid=19759185 |doi=10.1093/annonc/mdp337|doi-access=free }}</ref>

{| class="wikitable" |- ! Drug<ref>{{cite web|title=Cancer Care Ontario|url=http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=12424|work=Formulary|accessdate=2011-05-27}}</ref><ref>{{cite journal|last=Horning|first=SJ|author2=Williams J, Bartlett NL|title=Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492|journal=Journal of Clinical Oncology| date=March 2000 |volume=18|issue=5|pages=972–980|display-authors=etal|pmid=10694546|doi=10.1200/jco.2000.18.5.972}}</ref> !! Dose !! Mode !! Days |- | Doxorubicin || 25&nbsp;mg/m<sup>2</sup> || IV || Days 1 and 15 |- | Vinblastine || 6&nbsp;mg/m<sup>2</sup> || IV || Days 1 and 15 |- | Chlormethine || 6&nbsp;mg/m<sup>2</sup> || IV || Day 1 |- | Vincristine || 1.4&nbsp;mg/m<sup>2</sup> (max 2&nbsp;mg) || IV || Days 8 and 22 |- | Bleomycin || 5&nbsp;units/m<sup>2</sup> || IV || Days 8 and 22 |- | Etoposide || 60&nbsp;mg/m<sup>2</sup> || IV || Days 15, 16 |- | Prednisone || 40&nbsp;mg/m<sup>2</sup> || PO || Q2D |}

==References== <references /> ==External links== * [http://www.lymphomainfo.net/therapy/chemotherapy/stanfordv.html Lymphoma Information Network] * {{cite journal | pmid = 11821442 | volume=20 | issue=3 | title=Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial | date=February 2002 |vauthors=Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA | journal=J. Clin. Oncol. | pages=630–7 | doi=10.1200/jco.20.3.630}} * [http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=12424 Includes table for schedule]

{{Chemotherapeutic Agents}}

Category:Chemotherapy regimens used in lymphoma Category:Hodgkin lymphoma